SCHEMBL6830885

SCHEMBL6830885

Cc1cn([C@H]2C[C@H](OC(=O)OCC(C)c3cc(Br)ccc3[N+](=O)[O-])[C@@H](COC(=O)OCC(C)c3cc(Br)ccc3[N+](=O)[O-])O2)c(=O)[nH]c1=O

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RNASE1 P07998 1/20 0.45
ABCG2 Q9UNQ0 3/20 0.39
ABCB1 P08183 1/20 0.39
TK1 P04183 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6834411 0.94 RNASE1 (0.53) RNASE1TK1
SCHEMBL6834409 0.94 RNASE1 (0.53) RNASE1TK1
SCHEMBL6834133 0.92 RNASE1 (0.45) RNASE1ABCG2ABCB1TK1
SCHEMBL6836077 0.92 RNASE1 (0.45) RNASE1ABCG2ABCB1TK1
SCHEMBL6835969 0.92 POLB (0.45)
SCHEMBL13666505 0.92 POLB (0.45)
SCHEMBL6835970 0.92 POLB (0.45)
SCHEMBL7643615 0.90 RNASE1 (0.51) RNASE1ABCG2ABCB1TK1
SCHEMBL13666503 0.86 POLB (0.45)
SCHEMBL7263516 0.86 POLB (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6750335-B2 NUCLEOSIDE FOR USE IN THE GENERATION OF PREFERENTIAL OLIGONUCEOTIDES NIGU CHEMIE GMBH (DE) 2004-06-15 US disclosed
EP-1224198-B1 NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS NIGU CHEMIE GMBH (DE) 2003-04-23 EP disclosed
US-20020146737-A1 Nucleoside derivatives with photolabile protective groups NIGU CHEMIE GMBH (DE) 2002-10-10 US disclosed
EP-1224198-A1 NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS NIGU CHEMIE GMBH (DE) 2002-07-24 EP disclosed
WO-2001032671-A1 NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS NIGU CHEMIE GMBH (DE) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020146737-A1 Nucleoside derivatives with photolabile protective groups XRN2, XPA, NSUN2 RNASE1 339/4885ABCG2 1410/4885ABCB1 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.